Latest / Lung Cancer Considered
FDA Approval: Repotrectinib, a ROS1 and NTRK inhibitor
Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with a ROS1 gene fusion based on the single-arm, multi-cohort TRIDENT-1 trial.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.